Piper Jaffray analyst Tyler Van Buren lowered his price target Ovid Therapeutics to $14 after the company reported Q4 results and provided an updated outlook for 2019. The analyst, however, believes Ovid’s three programs could result in “significant upside” from current share levels. He keeps an Overweight rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.